ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

New CCSP And CCRU Awards Applications Under Review

January 17, 1986

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

It’s “High Noon” For Cancer, Vice President Says

October 2, 1998

Early-Stage HER2+ Breast Cancer Patients Are At Significant Risk Of Recurrence

December 26, 2008

In Brief: Brinkley Asks Subcommittee to Add $62.5 Million To NCI Budget for Unfunded Grants

May 11, 1979

13th Congress Advance Program Announcement Now Available

May 1, 1981